Precision Oncology Medicine
Developing a multi-pronged strategy to improve the accuracy, speed, and clinical impact of tumour genomic profiling for a nationwide oncology hospital chain.
Client
Nationwide Oncology Hospital Chain
Objective
Reduce Sequencing Turnaround Time
Timeline
10-Week Engagement
Key Focus
Heterogeneity Capture & Impact
A Multi-Pronged Strategy for Impact
We focused on three priority outcome areas to deliver a comprehensive strategy for improving the speed, accuracy, and clinical utility of genomic profiling.
1. Analytical Enhancement
Improve mutation detection across tissue and blood, including low-frequency subclones missed by single biopsies.
2. Operational Acceleration
Drastically reduce the biopsy-to-report time to $\le$ 7 calendar days, fitting within critical clinical decision windows.
3. Economic Justification
Provide evidence-based frameworks and value dossiers to support payer coverage and demonstrate clear cost-benefit.
Execution in Four Structured Phases
A revised 4-phase workflow ensured our recommendations were technically sound, clinically relevant, and commercially viable.
Mapped regulatory-approved sequencing tech and benchmarked lab turnaround times.
Created patient journey maps and modeled the impact of faster turnaround on treatment.
Reviewed payer positions on reimbursement and identified FDA/CE-marked solutions.
Delivered final scoring of platforms and a tailored pilot deployment framework.
Strategic Impact: From 14+ Days to Under 6
The client initiated an early pilot with a dual-modality approach: liquid biopsy as a first-line screen and tissue sequencing for high-resolution follow-up.
This new workflow led to faster treatment alignment and improved trial eligibility in advanced-stage patients, positioning the client as a frontrunner in time-sensitive, economically viable genomic precision oncology.
<6 Days
Average Turnaround Time
(Down from 14+ days)